Explore the latest news from Khondrion and its team.
NIJMEGEN, the Netherlands – Wednesday February 5th, 2020: Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies...
Study will examine impact on cognitive function from one of the most advanced disease-modifying drug treatments for mitochondrial disease in...
Khondrion becomes partner in DuSRA-VOILA collaboration
On Friday 10th January 2020, CEO Jan Smeitink participated in the Annual MitoAction Town Hall Meeting alongside other companies and organisations,...
Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces...
Members of the Khondrion team will be attending Mitochondrial Medicine 2019 on 11-13 December 2019. The event will bring together...
We recently sat down with Kasey Woleben, Co-founder, and Sophia Zilber, Board Member and Patient Registry Director of Cure Mito Foundation, to talk...
As 2021 draws to a close, Khondrion’s CEO Jan Smeitink reflects on the past year and the continued progress Khondrion has made in its development of...
Movement, the act or process of moving, the change of place or position or posture, is a complex process under the control of many different parts...
How did you first hear about Khondrion and the work the company is doing in mitochondrial disease? Jan Smeitink and I have been colleagues since the...
How did you first hear about Khondrion and the work the company is doing in mitochondrial disease? I first heard about Khondrion from CEO Jan...
Can you explain a little about the work that International Mito Patients does? International Mito Patients (IMP) is a global network of 16 national...
